nach oben

Erschienen in:

19.12.2016 | Original paper

Short-term and long-term survival of interval breast cancers taking into account prognostic features

verfasst von: Solenne Delacour-Billon, Anne Laure Mathieu-Wacquant, Mario Campone, Nathalie Auffret, Sophie Amossé, Corinne Allioux, Anne Cowppli-Bony, Florence Molinié

Erschienen in: Cancer Causes & Control | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this population-based study was to estimate short-term and long-term survival of interval breast cancers and to compare them to clinically detected cancers, taking into account prognostic features.

Methods

This study included all interval cancers and clinically detected cancers diagnosed in the Loire-Atlantique population-based cancer registry from 2000 to 2010 in women aged 50–76 years. We used the Pohar-Perme method to estimate 5- and 10 year net survival rates and a flexible parametric model to compare interval cancer and clinically detected cancer prognosis with and without adjustment for the main prognostic factors (age, stage, histological grade, and phenotype).

Results

This study included 813 interval cancers and 1,354 clinically detected cancers. Interval cancers were diagnosed at a significantly less advanced stage than clinically detected cancers, but more often with a triple-negative phenotype. Interval cancer age-standardised net survival was 88.0% at 5 years (95% CI 84.9–91.2) and 81.7% at 10 years (95% CI 76.9–86.9), whereas clinically detected cancer age-standardised net survival was 77.8% (95% CI 75.1–80.6) and 64.6% (95% CI 60.7–68.7), respectively. After adjustment for covariates, survival no longer differed between interval cancers and clinically detected cancers at 5 and 10 years.

Conclusion

Although the interval cancer net survival rate was higher, interval cancers had a similar short-term and long-term prognosis than clinically detected cancers after taking into account the main prognostic factors.

Binder-Foucard F, Bossard N, Delafosse P, Belot A, Woronoff A-S, Remontet L et al (2014) Cancer incidence and mortality in France over the 1980-2012 period: solid tumors. Rev Epidemiol Sante 62(2):95–108CrossRef

Cowan WK, Angus B, Gray JC, Lunt LG, al-Tamimi SR (2000) A study of interval breast cancer within the NHS breast screening programme. J Clin Pathol 53(2):140–146CrossRefPubMedPubMedCentral

Caumo F, Vecchiato F, Strabbioli M, Zorzi M, Baracco S, Ciatto S (2010) Interval cancers in breast cancer screening: comparison of stage and biological characteristics with screen-detected cancers or incident cancers in the absence of screening. Tumori 96(2):198–201PubMed

Kirsh VA, Chiarelli AM, Edwards SA, O’Malley FP, Shumak RS, Yaffe MJ et al (2011) Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program. J Natl Cancer I 103(12):942–950CrossRef

Rayson D, Payne JI, Abdolell M, Barnes PJ, MacIntosh RF, Foley T et al (2011) Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study. Clin Breast Cancer 11(1):27–32CrossRefPubMed

Chiarelli AM, Edwards SA, Sheppard AJ, Mirea L, Chong N, Paszat L et al (2012) Favourable prognostic factors of subsequent screen-detected breast cancers among women aged 50–69. Eur J Cancer Prev 21(6):499–506CrossRefPubMed

Domingo L, Blanch J, Servitja S, Corominas JM, Murta-Nascimento C, Rueda A et al (2013) Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers. Eur J Cancer Prev 22(1):21–28CrossRefPubMed

Renart-Vicens G, Puig-Vives M, Albanell J, Castañer F, Ferrer J, Carreras M et al (2014) Evaluation of the interval cancer rate and its determinants on the Girona Health Region’s early breast cancer detection program. BMC Cancer 14:558CrossRefPubMedPubMedCentral

José Bento M, Gonçalves G, Aguiar A, Antunes L, Veloso V, Rodrigues V (2014) Clinicopathological differences between interval and screen-detected breast cancers diagnosed within a screening programme in Northern Portugal. J Med Screen 21(2):104–109CrossRefPubMed

10.

Baré M, Torà N, Salas D, Sentís M, Ferrer J, Ibáñez J et al (2015) Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program. Breast Cancer Res Treat 154(2):403–415CrossRefPubMed

11.

Brekelmans CT, Peeters PH, Deurenberg JJ, Collette HJ (1995) Survival in interval breast cancer in the DOM screening programme. Eur J Cancer 31A(11):1830–1835CrossRefPubMed

12.

Shen Y, Yang Y, Inoue LYT, Munsell MF, Miller AB, Berry DA (2005) Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer I 97(16):1195–1203CrossRef

13.

Lawrence G, O’Sullivan E, Kearins O, Tappenden N, Martin K, Wallis M (2009) Screening histories of invasive breast cancers diagnosed 1989–2006 in the West Midlands, UK: variation with time and impact on 10-year survival. J Med Screen 16(4):186–192CrossRefPubMed

14.

Nagtegaal ID, Allgood PC, Duffy SW, Kearins O, Sullivan EO, Tappenden N et al (2011) Prognosis and pathology of screen-detected carcinomas: how different are they? Cancer 117(7):1360–1368CrossRefPubMed

15.

Raja MA, Hubbard A, Salman AR (2001) Interval breast cancer: is it a different type of breast cancer? Breast 10(2):100–108CrossRefPubMed

16.

Kalager M, Tamimi RM, Bretthauer M, Adami H-O (2012) Prognosis in women with interval breast cancer: population based observational cohort study. BMJ 345:e7536CrossRefPubMedPubMedCentral

17.

Holmberg LH, Tabar L, Adami HO, Bergström R (1986) Survival in breast cancer diagnosed between mammographic screening examinations. Lancet 2(8497):27–30CrossRefPubMed

18.

Peeters PH, Verbeek AL, Hendriks JH, Holland R, Mravunac M, Vooijs GP (1989) The occurrence of interval cancers in the Nijmegen screening programme. Br J Cancer 59(6):929–932CrossRefPubMedPubMedCentral

19.

Frisell J, von Rosen A, Wiege M, Nilsson B, Goldman S (1992) Interval cancer and survival in a randomized breast cancer screening trial in Stockholm. Breast Cancer Res Treat 24(1):11–16CrossRefPubMed

20.

Schroën AA, Wobbes T, van der Sluis RF (1996) Interval carcinomas of the breast: a group with intermediate outcome. J Surg Oncol 63(3):141–144CrossRefPubMed

21.

Collins S, Woodman CB, Threlfall A, Prior P (1998) Survival rates from interval cancer in NHS breast screening programme. BMJ 316(7134):832–833CrossRefPubMedPubMedCentral

22.

Bordás P, Jonsson H, Nyström L, Lenner P (2007) Survival from invasive breast cancer among interval cases in the mammography screening programmes of northern Sweden. Breast 16(1):47–54CrossRefPubMed

23.

Zackrisson S, Janzon L, Manjer J, Andersson I (2007) Improved survival rate for women with interval breast cancer—results from the breast cancer screening programme in Malmö, Sweden 1976–1999. J Med Screen 14(3):138–143CrossRefPubMed

24.

Perme MP, Stare J, Estève J (2012) On estimation in relative survival. Biometrics 68(1):113–120CrossRefPubMed

25.

Roche L, Danieli C, Belot A, Grosclaude P, Bouvier A-M, Velten M et al (2013) Cancer net survival on registry data: use of the new unbiased Pohar-Perme estimator and magnitude of the bias with the classical methods. Int J Cancer 132(10):2359–2369CrossRefPubMed

26.

Corazziari I, Quinn M, Capocaccia R (2004) Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40(15):2307–2316CrossRefPubMed

27.

Nelson CP, Lambert PC, Squire IB, Jones DR (2007) Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med 26(30):5486–5498CrossRefPubMed

28.

Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (2006) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn. Office for Official Publications of the European Communities, Luxembourg

29.

Santé Publique France (2013) Performance indicators of the breast cancer screening program, in Loire-Atlantique, from 2008 to 2010. http://invs.santepubliquefrance.fr/content/download/67068/258242/version/1/file/44_Loire_Atlantique_CUMUL2010.xls. Accessed 13 Oct 2016

30.

Exbrayat C, Poncet F, Guldenfels C, Soler-Michel P, Allioux C, Barraud-Krabe M (2012) Sensibilité et spécificité du programme de dépistage organisé du cancer du sein à partir des données de cinq départements français, 2002–2006. BEH 35–37:404–406

31.

Weber RJP, van Bommel RMG, Louwman MW, Nederend J, Voogd AC, Jansen FH et al (2016) Characteristics and prognosis of interval cancers after biennial screen-film or full-field digital screening mammography. Breast Cancer Res Treat 158(3):471–483CrossRefPubMed

32.

Vitak B, Stål O, Månson JC, Thomas BA, Arnesson LG, Ekelund L et al (1997) Interval cancers and cancers in non-attenders in the Ostergötland Mammographic Screening Programme. Duration between screening and diagnosis, S-phase fraction and distant recurrence. Eur J Cancer 33(9):1453–1460CrossRefPubMed

33.

McGuire WL (1978) Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5(4):428–433PubMed

34.

Russo J, Russo IH (1994) Toward a physiological approach to breast cancer prevention. Cancer Epidemiol Biomark Prev 3:353–364

35.

Lapidus RG, Nass SJ, Davidson NE (1998) The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol 3(1):85–94CrossRef

36.

Jatoi I, Chen BE, Anderson WF, Rosenberg PS (2007) Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 25(13):1683–1690CrossRefPubMed

Titel: Short-term and long-term survival of interval breast cancers taking into account prognostic features
verfasst von: Solenne Delacour-Billon
Anne Laure Mathieu-Wacquant
Mario Campone
Nathalie Auffret
Sophie Amossé
Corinne Allioux
Anne Cowppli-Bony
Florence Molinié
Publikationsdatum: 19.12.2016
Verlag: Springer International Publishing
Erschienen in: Cancer Causes & Control / Ausgabe 1/2017
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-016-0836-0

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Short-term and long-term survival of interval breast cancers taking into account prognostic features